Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

A Study to Evaluate the Efficacy and Safety of the Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Child-Pugh B and/or ECOG PS 2 Unresectable Hepatocellular Carcinoma

To evaluate the efficacy and safety of sintilimab combined with bevacizumab and liver protective support therapy in Child-Pugh B and/or ECOG PS 2 unresectable hepatocellular carcinoma

Inclusion Criteria:

• Advanced unresectable hepatocellular carcinoma confirmed by histology or cytology
• Age 20-79
• At least one measurable lesion defined in RECIST version 1.1
• Child Pugh grade B
• ECOG PS score 2
• The expected life is at least 90 days

Exclusion Criteria:

• Previously received anti-PD-1, PD-L1, PD-L2, CD137, CTLA-4 antibody treatment, or any other treatment that regulates T cells
• Received systemic corticosteroid or immunosuppressive therapy within 28 days before enrollment
• Complicated with autoimmune diseases or having a history of chronic or recurrent autoimmune diseases
• History of pleural or pericardial adhesions within 28 days before enrollment
• HIV antibody, HTV-Ⅰantibody, HCV antibody, hepatitis B surface protein antigen, hepatitis B surface protein antibody, hepatitis B core protein antibody or any detectable hepatitis B virus DNA test results were positive
• Multiple primary cancers (excluding completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, superficial bladder cancer, and any other cancer that has not recurred for at least 5 years)
• Brain or meningeal metastasis (unless asymptomatic and does not require treatment)
• Uncontrollable or serious cardiovascular disease.